Evidence map›Paper›PMID 41482412›Full record

ArticleIn vivo (Athens, Greece)

Integrated Bioinformatics and Experimental Analysis of Argonaute Family Members in Pancreatic Adenocarcinoma.

Ozcan Gulbey, Tugce Duran

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ozcan GulbeyTranslational and Clinical Research, Newcastle University, Newcastle upon Tyne, U.K.
Tugce DuranDepartment of Medical Genetics, Faculty of Medicine, KTO Karatay University, Konya, Türkiye tugce.duran@karatay.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPancreatic adenocarcinoma (PAAD) is an aggressive cancer type with high mortality rates. The Argonaute (AGO) gene/protein family is an evolutionary conserved family, which is responsible for post-transcriptional regulation of gene expression. Despite the fact that this family members (AGO1-4) have been linked to prognosis in some cancers, they have not been comprehensively investigated in PAAD. Therefore, this study investigates the role of AGO family members on PAAD. MATERIALS AND

methodsIn our research, bioinformatics analyses were performed to study gene, protein and methylation levels, prognostic importance, gene-gene and protein-protein interactions, enrichment analysis, and immune infiltration analysis, using online and publicly available platforms. Additionally, real-time PCR was used to check mRNA levels in the pancreatic cell line BxPC-3.

resultsmRNA (

conclusionThe findings of this study indicate the potential importance of AGO2 in terms of biological functions and prognostication in PAAD.

Indexed as

AdenocarcinomaArgonaute ProteinsComputational BiologyPancreatic NeoplasmsBiomarkers, TumorCell Line, TumorDNA MethylationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisProtein Interaction MapsRNA, MessengerAGO2 protein, humanArgonaute ProteinsBiomarkers, TumorRNA, MessengerAGOArgonautebiomarkerexpressionPAADpancreatic adenocarcinomaprognosis

Identifiers

PMID41482412
PMCPMC12764265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.